Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this… Read More
Automated Cell-based Assays: Novel tools overcome the barriers to drug discovery success By Helen Stewart-Miller and Kate Tointon In this article, we look at how commercial products and services are facilitating the automation of cell-based assays to advance drug discovery and accelerate the delivery of new medicines to patients. Cell-based… Read More
The Reality of Virtual Pharmaceutical Companies By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr We discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous task. The vagaries… Read More
How Mergers and Acquisitions Will Drive Oncology Research in 2019 By Dr Michael Seiler 2019 got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession. These ventures provide a window into key trends in oncology research, where investigators are likely… Read More
From Genotype to Phenotype: Leveraging functional genomics in oncology By Dr Menelas Pangalos & Steve Rees et al. A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine. In 2011, AstraZeneca initiated a strategic ‘5R Framework’… Read More
Fostering Multidisciplinary Collaboration in Drug Discovery By Professor Zeynep Erden, et al. Drug discovery teams combine specialists with in-depth knowledge from a variety of scientific disciplines. Such diversity in thought worlds poses a challenging exercise in cross-disciplinary collaboration and project coordination. Based on a longitudinal field study of five projects… Read More
3D Organoid Cell Culture - Optimising disease models for research and drug discovery By Dr Amanda Linkous, Hilary Sherman, Iris Li and Dr Richard M. Eglen The use of human-induced pluripotent stem cells (HiPSCs) continues to grow in three-dimensional (3D) spheroid and organoid culture. Although advances in 3D cell culture… Read More
Beyond SEND: Leveraging non-clinical data to drive translational research forward By Katherine Briggs, et al., This article will discuss some of the potential use cases that Standard for Exchange of Nonclinical Data (SEND), datasets can support. Both to advance translational research across multiple research sites and also to drive efficiencies… Read More
3D Cell Culture - Engineering Composable, Disease-Tunable 3D Human Microtissues for Drug Discovery By Dr Patrick Guye, Dr Eva Thoma and Dr Olivier Frey In this article, we will share some of what we have learned over the past 10 years as pioneers in the 3D cell culture space and… Read More
Genetically-Engineered Models: The Value of Precious GEMs By Dr Megan M. MacBride Genetically-engineered animal models (GEMs) are critical tools for drug discovery and development, but intellectual property (IP) concerns can complicate access. As pharma and biotech increasingly outsource R&D activities to universities, careful scrutiny is required to ensure adherence to… Read More
The Future Of Drug Discovery - Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds,… Read More
Induced Pluripotent Stem Cells (iPSCs) - Unlocking their full potential for Drug Discovery By Abby Edwards and Dr Richard Massey Human stem cells were once viewed primarily as regenerative materials for tissue repair through cell therapies. However, advances in technologies and protocols mean that induced pluripotent stem cells (iPSCs) are… Read More
Disruptive Approaches To Accelerate Drug Discovery and Development (Part 2) By Dr Anton Fliri, et al. Part 2: Emergent intelligence, a new paradigm for drug discovery. (You can read part 1 of disruptive approaches to accelerate drug discovery and development linked here.) The staggering clinical trial failure rate of experimental… Read More
Astrazeneca R&D - Improving Drug Development Productivity With Better Predictivity By Dr Menelas Pangalos & Steve Rees et al. Changing demands in global healthcare over the past 15 years have led to greater complexity and spiralling costs in drug development. The average price tag of taking a new drug from… Read More
Bringing Immuno-Oncology Together: How An Immunologist & Oncologist Collaborate By Dr Julia Schuler and Dr Louise Brackenbury For many years, immunology and oncology operated as separate disciplines within drug discovery. However, recent advances in immuno-oncology (IO) have demonstrated what can be achieved when the two disciplines join forces in developing… Read More
Natural Killer Cells - How NK Cell Therapy Will Transform Immunotherapy By Dr Azusa Tanaka and Dr Michael Seiler Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours – a major shift in oncology treatment and the battle… Read More